BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

BANGALORE, Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top ...

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...

BANGALORE (Reuters) - Biocon Ltd , India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive ...

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units ...

Gov. Gavin Newsom announced on Thursday that the first state-made insulin would be available at the start of 2026.California’s CalRx® Insulin Glargine in 3mL pen form will be $55 per five-pack. That's ...

Members of the editorial and news staff of the Los Angeles magazine and the Engine Vision Media Network were not involved in the creation of this content. A new agreement between Biocon Biologics Ltd.